Core Insights - The rapid development of the domestic pharmaceutical industry has significantly advanced the raw material drug sector, particularly in the "sartan" antihypertensive drug market [1][2] Group 1: Market Overview - The global consumption of sartan raw materials from 2016 to 2022 reached 34,282.2 tons, with valsartan being the most consumed at 9,925.53 tons [2][3] - The highest growth rate in consumption was observed for aliskiren ester, with a compound annual growth rate (CAGR) of 227.76% [4][5] - The top three consumed sartan raw materials in China from 2016 to 2022 were irbesartan, valsartan, and aliskiren ester, with total consumption of 298.96 tons, 172.73 tons, and 37.19 tons respectively [10][21] Group 2: Sales Performance - The global sales of sartan formulations in 2022 reached $23.115 billion, with a CAGR of 12.19% from 2018 to 2022 [8][20] - The leading active ingredient in global sartan formulation sales in 2022 was sacubitril/valsartan, generating $6.941 billion, significantly surpassing other sartan drugs [6][7] - In China, the sales of sartan formulations from 2016 to 2022 totaled 240.37 billion yuan for valsartan, 134.41 billion yuan for irbesartan, and 79.20 billion yuan for losartan [21][22] Group 3: Competitive Landscape - Major companies in the sartan raw material export market include Huahai Pharmaceutical, Tianyu Pharmaceutical, and Shanghai Pharmaceuticals, with Huahai leading in export volume [14][15] - The domestic market for angiotensin II receptor antagonists (sartans) accounted for 26.17% of the total antihypertensive drug market in 2022, indicating a strong market presence [17][20] - The competitive landscape is influenced by the approval of domestic generic drugs and centralized procurement policies, which are expected to drive growth in the sartan raw material and formulation markets [8][20] Group 4: Future Outlook - The report predicts continued growth in the sartan raw material and formulation markets, driven by increasing demand and favorable policy environments [1][24] - Aliskiren ester, a domestically developed angiotensin receptor antagonist, is expected to see significant growth, especially as its compound patent expires in July 2026 [24]

2024年，原料药板块盈利能力迎来全面改善，毛利率同比提升1.58个百分点至38%，净利率大幅攀升 4.97个百分点至12.79%，创下近三年新高。分季度看，Q4成为全年亮点，毛利率同比跳涨5.47个百分点 至40.29%，净利率同比提升13.89个百分点。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年，32家原料药上市公司交出了一份稳健的成绩单，全年实现营业收入1176.77亿元，同比增长 6.74%，成功扭转了2023年因价格下行和去库存导致的低迷态势。分季度来看，行业呈现出显著的"前 低后高"特征。Q1营收同比微降0.56%，但从Q2开始，随着全球下游厂商去库存周期接近尾声，叠加部 分新产品进入放量期，Q2-Q4营收同比分别增长9.04%、12.64%、8.76%。 值得注意的是，尽管2025年Q1营收同比小幅下滑0.48%至295.46亿元，但环比仍增长5.77%，显示出行 业在经历阶段性调整后逐步企稳的态势。这一表现与全球医药供应链的修复节奏基本同步，尤其是欧美 市场对原料药需求的温和回升，为行业提供了支撑。 利润端的表现则更具爆发力，2024年原料药板块归母 ...

Group 1 - The company will hold an Investor Reception Day on May 23, 2025, from 9:30 AM to 12:30 PM at its headquarters in Linhai, Zhejiang [2][3] - The event aims to enhance corporate governance and investor relations by facilitating communication between the company and investors regarding operational performance, development strategies, and governance issues [2][3] - Attendees will include key executives such as the President, CFO, and other senior management [3] Group 2 - Investors interested in attending must register in advance between May 16 and May 22, 2025, and provide necessary identification documents [4][6] - The company will cover the cost of lunch for attendees, while other expenses will be borne by the investors [6] - Post-event, the company will disclose the meeting's outcomes through various media channels [6] Group 3 - The company will also hold its 2024 Annual Shareholders' Meeting on May 23, 2025, at 2:00 PM, utilizing both on-site and online voting methods [9][10] - The meeting will allow shareholders to vote on various proposals, including the election of board members [12][14] - Shareholders must register to attend the meeting and can delegate their voting rights to a proxy if unable to attend [19][21]

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 2025-057 号 | | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | 浙江华海药业股份有限公司 关于举办投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 为进一步提高公司治理水平，加强投资者关系管理，增进公司与广大投资者的 沟通和交流，浙江华海药业股份有限公司（以下简称"公司"）定于 2025 年 5 月 23 日上午举行投资者接待日活动，届时将针对公司的经营情况、发展战略、公司治理 等投资者关心的问题与广大投资者进行现场的沟通和交流，同时广泛听取投资者的 意见和建议。本次投资者接待日活动具体情况如下： 一、活动召开的时间、地点及方式 活动召开时间：2025 年 5 月 23 日上午 9:30—12:30； 活动召开地点：浙江省临海市汛桥镇浙江华海药业股份有限公司； 活动召开方式：现场召开。 二、公司参加人员 出席本次活动的人员有：公司董事兼总裁陈保华先生，公 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2025-058 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）于2025年4月28日召开第 八届董事会第三次会议，会议审议通过了《关于提议召开2024年年度股东大会 的议案》，公司将于2025年5月23日召开2024年年度股东大会，并已于2025年4月 30日在中国证券报、上海证券报、证券时报、证券日报和上海证券交易所网站 （www.sse.com.cn）上刊登了《浙江华海药业股份有限公司关于召开2024年年 度股东大会的通知》。为进一步保护投资者的合法权益，为公司股东行使股东大 会表决权提供便利，现将有关事项再次提示如下： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 召开地点：浙江省临海市汛桥浙江华海药业股份有限公司会议室 (五)网络投票的系统、起止日期和投 ...

浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2024 年年度股东大会资料 股票简称：华海药业 股票代码：600521 地点：浙江省临海市汛桥镇浙江华海药业股份有限公司会议室 会议议程 一、与会者签到 浙江·台州·临海 二零二五年五月二十三日 浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2024 年年度股东大会会议议程 时间：2025 年 5 月 23 日下午 14 点 00 分 二、大会开始，主持人讲话 三、审议议案 1、审议《公司 2024 年度董事会工作报告》； 2、审议《公司 2024 年度监事会工作报告》； 3、审议《公司 2024 年度财务决算报告》； 4、审议《公司 2024 年度利润分配方案》； 5、审议《公司 2024 年年度报告及其摘要》； 6、审议《关于选举公司第九届董事会非独立董事的议案》； 6.01 审议《关于选举李宏先生为公司第九届董事会非独立董事的议案》； 6.02 审议《关于选举陈保华先生为公司第九届董事会非独立董事的议案》； 6.03 审议《关于选举祝永华先生为公司第九届董事会非独立董事的议案》； 6.04 审议《关于选举单伟 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2025-058 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）于2025年4月28日召开第 八届董事会第三次会议，会议审议通过了《关于提议召开2024年年度股东大会 的议案》，公司将于2025年5月23日召开2024年年度股东大会，并已于2025年4月 （www.sse.com.cn）上刊登了《浙江华海药业股份有限公司关于召开2024年年 度股东大会的通知》。为进一步保护投资者的合法权益，为公司股东行使股东大 会表决权提供便利，现将有关事项再次提示如下： 一、 召开会议的基本情况 (一)股东大会类型和届次 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 23 日 14 点 00 分 召开地点：浙江省临海市汛桥浙江华海药业股份有限公司会议室 (五)网络投票的系统、起 ...

Summary of Haida Group's Conference Call Company Overview - **Company**: Haida Group - **Industry**: Animal Feed and Aquaculture Key Points and Arguments - **International Market Expansion**: Haida Group is actively expanding into overseas markets, particularly in emerging regions such as Asia-Pacific, Latin America, and Africa, aiming for 7.2 million tons of overseas feed sales by 2030 [2][8] - **Profitability in Overseas Markets**: The profitability in overseas markets is higher than in domestic markets due to a more relaxed competitive environment and structural opportunities, especially in aquaculture feed, where the Asia-Pacific region holds 70% of the global market share [2][5] - **Aggressive Business Strategy**: The company adopts an aggressive business strategy prioritizing sales volume, reducing costs through formulation and procurement, and leveraging economies of scale to lower manufacturing costs before pursuing profit per ton [2][6] - **Integrated Industry Chain Approach**: Haida Group implements an integrated industry chain strategy, combining shrimp seedlings, animal health, and feed technology services to provide comprehensive solutions that enhance survival rates and effectiveness in aquaculture, particularly for large farm owners [2][6] - **Focus on Key Countries**: The company emphasizes a strategy of deepening its presence in key countries, achieving significant market share in specific regions, such as a 45% market share in the Vietnamese duckling market [3][6] Additional Important Insights - **Domestic Market Growth**: In the domestic market, Haida Group's pig feed business showed strong growth, with a 30% increase in Q1 and a 40% increase in April 2025, supported by a successful OEM model that builds customer trust and brand premium [4][9] - **Financial Projections**: The company raised its 2025 target market value to 105 billion yuan, based on a feed growth forecast of 13% to 15%, with plans to achieve 7 billion yuan in feed business profits by 2030 [4][13][14] - **Water Feed Business Outlook**: The water feed business is expected to exceed the annual growth target of 10% to 15% due to stable fish prices and recovery trends in specific feed categories [11] - **Contribution from Pig Farming**: Despite facing downward pressure from the pig cycle, pig farming is projected to contribute 10 billion yuan in profits for 2025, with ongoing exploration of new breeding models to reduce costs [12] - **Future Growth Path**: The growth trajectory for Haida Group is expected to be steep, with significant improvements anticipated in 2025 and 2026, and no ceiling for overseas business expansion [15]

Summary of Key Points from Conference Call Records Industry Overview - The medical device sector is expected to see investment opportunities in Q2 2025 due to steady equipment updates and the end of inventory clearance by companies [1][5] - The pharmaceutical industry is projected to perform relatively flat in 2025, ranking between 10th to 15th among 31 primary industries [2] Key Insights on Specific Sectors Innovative Drugs - The innovative drug sector showed strong performance in Q1 2025, with companies like BeiGene reporting a 50% year-over-year revenue increase, and others like Innovent and Rongchang Biotech seeing growth rates of over 40% and nearly 60%, respectively [3] - Small-cap companies like Aidi Kang experienced triple-digit growth, indicating a robust market for innovative drugs [3] Medical Devices - The medical device market is witnessing a significant uptick in procurement, with a nearly 70% year-over-year increase in bidding for equipment in Q1 2025 [3][17] - Major imaging equipment and radiation therapy devices are in high demand, particularly in tertiary hospitals, with procurement rates accelerating in eastern provinces like Jiangsu and Guangdong [20][22] Traditional Chinese Medicine (TCM) - The TCM sector is expected to perform well in Q2 and Q3 2025, driven by domestic demand expansion, aging population, and state-owned enterprise reforms [1][9] - Key recommended stocks include China Resources Sanjiu, Dong-E E-Jiao, and Jianmin, with valuations currently at 15-17 times earnings [9] Pharmaceutical Retail - The pharmaceutical retail sector is undergoing a supply-side clearance, with leading chains focusing on cost reduction and efficiency to ensure profit growth [11] - Companies like Yifeng Pharmacy and Lao Bai Xing are highlighted for their operational efficiency [11] API Market - The active pharmaceutical ingredient (API) market is stabilizing after years of price declines, with companies like Huahai Pharmaceutical and Tianyu Co. reporting stable revenues around 1.4 billion [12] Future Trends and Events - Upcoming academic conferences and significant data releases from companies are expected to impact market sentiment positively [6] - The medical device sector is projected to see concentrated procurement activity in Q3 and Q4 2025, following a government push for large-scale equipment updates [17][18] Additional Insights - The in-vitro diagnostics (IVD) sector is facing pressure due to price reductions and tax adjustments, but a potential recovery is anticipated by the end of 2025 [8] - The high-value consumables market remains stable, with companies in orthopedics showing strong performance post-collective procurement [8] - The construction of tightly-knit county medical communities is expected to drive procurement in these areas, with a goal of 90% completion by the end of 2025 [23]

长江商报消息 ●长江商报记者 张璐 在原料药、制剂垂直一体化的产业链优势下，华海药业（600521.SH）盈利能力保持稳定增长。 近日，华海药业发布2024年度业绩报告，报告期内，公司实现营收95.47亿元，同比增长14.91%；净利 润为11.19亿元，同比增长34.74%。 长江商报记者注意到，华海药业持续推进全球销售网络建设。2024年，公司原料药业务销售收入36.46 亿元，同比增长15.39%，覆盖全球上百个国家和地区，新增客户超150家，国际化布局进一步深化。 同时，华海药业坚持创新驱动战略，2022年—2024年研发费用逐年上涨，累计达28.96亿元。 海外营收占比达47.27% 华海药业发布的2024年度业绩报告显示，2024年，公司实现营收95.47亿元，同比增长14.91%；实现净 利润11.19亿元，同比增长34.74%；实现扣非净利润11.29亿元，同比增长27.10%。 具体来看，面对全球经济变化及国内政策调整，华海药业采取了以"聚焦核心战略，全面精益增效"的发 展策略。2024年，公司中间体原料药业务实现销售收入36.46亿元，同比增长15.39%，该业务营收占比 达到38.19% ...